<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656470</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000996</org_study_id>
    <nct_id>NCT04656470</nct_id>
  </id_info>
  <brief_title>Neuroimaging Studies of Dexmedetomidine- and Ketamine-Induced Analgesia</brief_title>
  <official_title>Neuroimaging Studies of Dexmedetomidine- and Ketamine-Induced Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine&#xD;
      and ketamine in order to understand their analgesic effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, participants will be given dexmedetomidine and ketamine on seperate visits&#xD;
      using a crossover trial design. fMRI will be conducted during this time. Cognitive&#xD;
      assessments and pain monitoring will be administered at various points before and after&#xD;
      ketamine or dexmedetomidine are administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to be delivered either dexmedetomidine or ketamine anesthesia during the first study visit. During the second study visit, patients will receive the alternative intervention.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Dexmedetomidine on Pain Processing Circuitry</measure>
    <time_frame>Change in brain functional connectivity between baseline pain and dexmedetomidine pain during the fMRI visit, an average of 90 minutes</time_frame>
    <description>fMRI data will be used to compare changes in brain connectivity due to pain using functional network and seed-based correlation analyses when a pain cuff (Hokanson Rapid Cuff Inflator) is inflated during baseline and dexmedetomidine analgesia periods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ketamine on Pain Processing Circuitry</measure>
    <time_frame>Change in brain functional connectivity between baseline pain and ketamine pain during the fMRI visit, an average of 90 minutes</time_frame>
    <description>fMRI data will be used to compare changes in brain connectivity due to pain using functional network and seed-based correlation analyses when a pain cuff (Hokanson Rapid Cuff Inflator) is inflated during baseline and ketamine analgesia periods.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Analgesia</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine, Then Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the first study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.7mcg/kg/hr will be maintained for an additional 20-30 minutes. On the second study visit, patients will be delivered ketamine anesthesia. 0.5mg/kg of ketamine solution will be infused gradually over 10 minutes and then up to 0.5mg/kg/hr will be maintained for an additional 20-30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine, Then Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the first study visit, patients will be delivered ketamine anesthesia. 0.5mg/kg of ketamine solution will be infused gradually over 10 minutes and then up to 0.5mg/kg/hr will be maintained for an additional 20-30 minutes. On the second study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.7mcg/kg/hr will be maintained for an additional 20-30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.</description>
    <arm_group_label>Dexmedetomidine, Then Ketamine</arm_group_label>
    <arm_group_label>Ketamine, Then Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Patients will be delivered ketamine anesthesia to gain greater understanding of its analgesic effects.</description>
    <arm_group_label>Dexmedetomidine, Then Ketamine</arm_group_label>
    <arm_group_label>Ketamine, Then Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18 to 45&#xD;
&#xD;
          -  Normal body weight and habitus, BMI â‰¤ 30&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status classification P1&#xD;
&#xD;
          -  Active health insurance coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiovascular: myocardial infarction, coronary artery disease, peripheral vascular&#xD;
             disease, arrhythmia, congestive heart failure, valvular disease, hypertension&#xD;
&#xD;
          -  Respiratory: bronchitis, chronic obstructive pulmonary disease, smoking, shortness of&#xD;
             breath&#xD;
&#xD;
          -  Hepatic: hepatitis, jaundice, ascites&#xD;
&#xD;
          -  Neurologic: seizure, stroke, positive neurologic findings on neurologic examination,&#xD;
             multiple sclerosis, Meniere's disease, Parkinson's disease, neuropathy, peripheral&#xD;
             stenosis&#xD;
&#xD;
          -  Gastrointestinal: esophageal reflux, hiatal hernia, ulcer&#xD;
&#xD;
          -  Endocrine: diabetes, thyroid disease&#xD;
&#xD;
          -  Renal: acute or chronic severe renal insufficiency&#xD;
&#xD;
          -  Hematologic: blood dyscrasias, anemia, coagulopathies, on anticoagulant therapy&#xD;
&#xD;
          -  Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or&#xD;
             family history of malignant hyperthermia&#xD;
&#xD;
          -  Psychiatric: history or treatment for an active psychiatric problem, depression&#xD;
&#xD;
          -  Reproductive: pregnancy, breast-feeding&#xD;
&#xD;
          -  Medications: regular use of prescription and non-prescription medications expected to&#xD;
             affect CNS function, St. John's Wort&#xD;
&#xD;
          -  Allergies: labetalol, ondansetron, glycopyrrolate, ketamine, zofran, haloperidol,&#xD;
             phenylephrine&#xD;
&#xD;
          -  Dermatologic: ulcerative skin conditions or other dermatologic conditions which could&#xD;
             interfere with blood pressure cuff placement.&#xD;
&#xD;
          -  MRI reasons for exclusion: History of head trauma, surgical aneurysm clips, cardiac&#xD;
             pacemaker, prosthetic heart valve, neurostimulator, implanted pumps, cochlear&#xD;
             implants, metal rods, plates, or screws, intrauterine device, hearing aid, dentures,&#xD;
             metal injury to eyes, metallic tattoos anywhere on the body or near the eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oluwaseun Johnson-Akeju, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oluwaseun Johnson-Akeju, MD, MMSc</last_name>
    <phone>6177427200</phone>
    <email>oluwaseun.akeju@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katia Colon, BS</last_name>
    <phone>6177265186</phone>
    <email>kmcolon@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Oluwaseun Johnson-Akeju, MD, MMSc</investigator_full_name>
    <investigator_title>Associate Professor of Anaesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

